Hanjo Hennemann studied biology and obtained his Ph.D. in genetics at the University of Bonn, Germany. As a Feodor Lynen Fellow (Alexander von Humboldt Foundation), he completed a postdoctoral stay at the University of California, San Diego. He established his research group at the Caesar Research Center in Bonn and co-founded and led a biopharmaceutical company (peptide-based therapeutics) as CEO/CSO. He later co-founded Verovaccines GmbH (vaccines for animals) in 2017, which he heads as Managing Director/CEO. The company developed a proprietary technology platform for subunit vaccines that offers unique advantages in vaccine generation, combination, manufacturing and development.
December 15th, 2023